ABSI vs ABCL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ABSI · Absci Corp$7.51 ▼ 7.97%
ABCL · AbCellera Biologics$9.69 ▼ 7.45%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ABSI +153.7%
- ABCL +171.4%
Head to head
| Metric | ABSI | ABCL |
|---|---|---|
| Price | $7.51 | $9.69 |
| Change today | ▼ 7.97% | ▼ 7.45% |
| Market cap | $1.30B | $3.16B |
| Return, 3 months | -15.0% | -8.7% |
| Return, year to date | +115.2% | +183.3% |
| Return, 1 year | +156.3% | +176.1% |
| P/E (TTM) | – | – |
| P/B | 5.9 | 3.0 |
| P/E percentile vs own 5y | 6th | 6th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -19.6% | +18.8% |
| Net profit growth (YoY) | -16.0% | +28.6% |
| Gross margin | – | – |
| Operating margin | -9,155.3% | -275.7% |
| Net margin | -8,451.3% | -218.6% |
| Return on equity | -58.6% | -14.6% |
| Analyst target vs. price | +96.4% | +99.5% |
| Analyst buy share | 89% | 89% |
| RSI (14) | 39 | 34 |
| 30-day volatility | 118.1% | 80.2% |
| Max drawdown, 1 year | -42.8% | -40.1% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ABCL is the largest of the group by market value.
- ABCL has returned the most over the past year.
- ABCL is growing revenue fastest.
- ABCL keeps the most profit per dollar of sales.
- ABCL has been the calmest stock over the last 30 days.